Cns Pharmaceuticals Inc (CNSP) Stock Price, Quote & News

Company Profile

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, develops anti-cancer drug candidates for the treatment of brain and central nervous system (CNS) tumors. The company's drug candidates include TPI 287 and Berubicin, which are in Phase 2 clinical trial for the treatment of glioblastoma and other CNS malignancies. It has license agreement with Cortice Biosciences, Inc. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Industry: Biotechnology

Sector: Healthcare

Phone: 800-946-9185

Website: www.cnspharma.com

Address:

2100 West Loop South, Suite 900, Houston, United States

youbi336 Jun. 16 at 10:06 PM

$CNSP Fingers crossed for delisting! It's going well as of rn!

0 · Reply

ribockski Jun. 15 at 6:11 AM

$CNSP $CTKB $CRNX $NVDA

0 · Reply

AnUnwiseInvestor Jun. 15 at 2:55 AM

$DJT na now we are interested in why you stand up for such assassins. And $CNSP is a shit stock btw…

0 · Reply

kl7777 Jun. 13 at 11:06 PM

$CNSP Rewriting for correct address of X below for some. I understand negativities on the company. Some may disagree and not care losing more money, excluding the shorts, but price needs to go up for people to sell for smaller losses. Others can leave messages at cns_pharma on X account.

0 · Reply

teedatrader Jun. 13 at 7:52 PM

$CNSP praying this delists soon. so many lost so much here in February, don't want other to get sucked into the trap.

1 · Reply

NetworkNewsWire Jun. 13 at 5:15 PM

New Study Shows TTFields Amplify Immune Attack Against Brain Cancer $CNSP https://ibn.fm/ZBFXn #biomedstocks #Cancer

0 · Reply

TheDrunkTrader69 Jun. 13 at 3:05 PM

$CNSP .10 is new bottom dont say i didnt warn you , i use to love this stock but they will do you dirty.

0 · Reply

Adorno99 Jun. 13 at 2:47 PM

$CNSP In here and will add if it goes lower though I think the downside is minimal. Then, just wait for it to pop

0 · Reply

Tradingistheway Jun. 13 at 7:57 AM

$CNSP .92 then straight to $5

0 · Reply

youbi336 Jun. 12 at 8:03 PM

$CNSP I've been here for quite some time and there's always hopeful investors that come here thinking they would make money out of this. Let me tell you, this is a black hole. It has no bottom. It will take your money then continue down. Then they will r/s and do it all over again. The CEO is a scumbag. He knew Berubicin doesn't work and licensed TPI 287 for the moment its trial fails. He immediately switched to the new drug after having promised patients and shareholders that 2025 would be a great year. Guess what, far from it. Take your money elsewhere! NFA

0 · Reply

CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit

May 16, 2025, 8:05 AM EDT - 4 weeks ago

CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 13, 2025, 9:35 AM EDT - 4 weeks ago

CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

May 13, 2025, 7:00 AM EDT - 4 weeks ago

CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287

Apr 1, 2025, 8:05 AM EDT - 2 months ago

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Mar 25, 2025, 12:05 PM EDT - 2 months ago

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

Mar 25, 2025, 8:00 AM EDT - 2 months ago

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Feb 26, 2025, 9:05 AM EST - 3 months ago

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Feb 20, 2025, 9:00 AM EST - 4 months ago

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Feb 19, 2025, 9:00 AM EST - 4 months ago

CNS Pharmaceuticals, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:30 AM EST - 4 months ago

CNS Pharmaceuticals Announces Reverse Stock Split

Feb 18, 2025, 9:00 AM EST - 4 months ago

CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit

Feb 10, 2025, 8:00 AM EST - 4 months ago

CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference

Dec 5, 2024, 9:10 AM EST - 6 months ago

CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024

Nov 25, 2024, 9:00 AM EST - 7 months ago

CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy

Nov 18, 2024, 8:55 AM EST - 7 months ago

CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024)

Nov 15, 2024, 9:10 AM EST - 7 months ago

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

Nov 4, 2024, 9:15 AM EST - 8 months ago

CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment

Nov 1, 2024, 9:00 AM EDT - 8 months ago

CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

Oct 23, 2024, 2:50 PM EDT - 8 months ago

CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 10, 2024, 9:00 AM EDT - 8 months ago

CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment

Oct 8, 2024, 9:15 AM EDT - 8 months ago

CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC

Sep 23, 2024, 9:00 AM EDT - 9 months ago

CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum

Sep 12, 2024, 9:00 AM EDT - 9 months ago

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

Sep 4, 2024, 9:05 AM EDT - 10 months ago

CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 10 months ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Aug 27, 2024, 9:10 AM EDT - 10 months ago

CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

Aug 22, 2024, 9:15 AM EDT - 10 months ago

CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment

Aug 15, 2024, 8:00 AM EDT - 10 months ago

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 7:00 AM EDT - 11 months ago

CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies

Jul 25, 2024, 9:05 AM EDT - 11 months ago

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

Jul 16, 2024, 9:15 AM EDT - 11 months ago

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Jul 3, 2024, 11:10 AM EDT - 1 year ago

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

May 20, 2024, 8:30 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

May 16, 2024, 7:45 AM EDT - 1 year ago

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Apr 23, 2024, 9:00 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Apr 22, 2024, 10:15 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Apr 1, 2024, 5:00 PM EDT - 1 year ago

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Apr 1, 2024, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Present at Two Investor Conferences in April

Feb 9, 2024, 8:35 AM EST - 1 year ago

Top 5 Health Care Stocks That Are Preparing To Pump In February

GILD REVB ZLAB

Jan 29, 2024, 9:00 PM EST - 1 year ago

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

Jan 18, 2024, 8:45 AM EST - 1 year ago

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Jan 17, 2024, 8:45 AM EST - 1 year ago

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

Dec 18, 2023, 8:35 AM EST - 1 year ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Dec 6, 2023, 9:00 AM EST - 1 year ago

How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure

Nov 22, 2023, 9:05 AM EST - 1 year ago

CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

Nov 16, 2023, 10:00 AM EST - 1 year ago

CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate

Nov 15, 2023, 8:00 AM EST - 1 year ago

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

Oct 19, 2023, 9:05 AM EDT - 1 year ago

CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference

Oct 16, 2023, 9:00 AM EDT - 1 year ago

Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals' Innovative Approach To Treatment Could Offer Hope

youbi336 Jun. 16 at 10:06 PM

$CNSP Fingers crossed for delisting! It's going well as of rn!

0 · Reply

ribockski Jun. 15 at 6:11 AM

$CNSP $CTKB $CRNX $NVDA

0 · Reply

AnUnwiseInvestor Jun. 15 at 2:55 AM

$DJT na now we are interested in why you stand up for such assassins. And $CNSP is a shit stock btw…

0 · Reply

kl7777 Jun. 13 at 11:06 PM

0 · Reply

teedatrader Jun. 13 at 7:52 PM

$CNSP praying this delists soon. so many lost so much here in February, don't want other to get sucked into the trap.

1 · Reply

NetworkNewsWire Jun. 13 at 5:15 PM

New Study Shows TTFields Amplify Immune Attack Against Brain Cancer $CNSP https://ibn.fm/ZBFXn #biomedstocks #Cancer

0 · Reply

TheDrunkTrader69 Jun. 13 at 3:05 PM

$CNSP .10 is new bottom dont say i didnt warn you , i use to love this stock but they will do you dirty.

0 · Reply

Adorno99 Jun. 13 at 2:47 PM

$CNSP In here and will add if it goes lower though I think the downside is minimal. Then, just wait for it to pop

0 · Reply

Tradingistheway Jun. 13 at 7:57 AM

$CNSP .92 then straight to $5

0 · Reply

youbi336 Jun. 12 at 8:03 PM

0 · Reply

inthebay Jun. 12 at 7:41 PM

$CNSP I’m in this one.

0 · Reply

TheDrunkTrader69 Jun. 12 at 7:32 PM

$CNSP Have my re entry set at .10 seems like this stocks favorite # 😀

0 · Reply

shock89 Jun. 12 at 4:32 PM

$CNSP Inflow is much more than outflow

0 · Reply

TomCPA Jun. 11 at 4:59 PM

$CNSP Add (2/4)

0 · Reply

TheDrunkTrader69 Jun. 11 at 4:47 PM

$CNSP Sorry folks CEO needs a new yacht gonna have to take it down to .10 again but its all still ok, ? Im making good profits @ OSTX RLAY ABCL RCKT all good 👍

0 · Reply

Hdheheh Jun. 11 at 3:55 PM

$CNSP how loww can it gooooo

0 · Reply

simonsteve Jun. 11 at 2:31 PM

$CNSP who bought at $440?

1 · Reply

simonsteve Jun. 11 at 2:31 PM

$CNSP how is it 52week high of $440 😳😳😳

1 · Reply

shock89 Jun. 11 at 2:04 PM

$CNSP Average is $2.11

0 · Reply

youbi336 Jun. 11 at 1:55 PM

$CNSP New investors are about to get wrecked, lol

0 · Reply

simonsteve Jun. 10 at 7:57 PM

$CNSP not selling for shit 2026 here I come 🤑🤑🤑🤑

0 · Reply

youbi336 Jun. 10 at 7:34 PM

$CNSP Time for this shitty company to go back under $1.0 where it belongs, then hopefully OTC so that it may never scam anyone again

1 · Reply

Market Cap	4.41M
Revenue (ttm)	0.00
Net Income (ttm)	-14.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	240,300
Avg Vol	2,073,396
Day's Range	N/A - N/A
Shares Out	5.46M
Stochastic %K	3%
Beta	2.65
Analysts	Hold
Price Target	$7.00